Elicio Therapeutics, Inc. — Director's Dealing 2021

Feb 12, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Angion Biomedica Corp. (ANGN)
CIK: 0001601485
Period of Report: 2021-02-09

Reporting Person: OMENN GILBERT S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-09	Common Stock	C	23483	$11.57	Acquired	42152	Indirect
2021-02-09	Common Stock	C	23391	$11.57	Acquired	65543	Indirect
2021-02-09	Common Stock	C	14783	$11.57	Acquired	80326	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-09	Convertible Promissory Note	$16	C		Disposed		Common Stock ()	Indirect
2021-02-09	Convertible Promissory Note	$16	C		Disposed		Common Stock ()	Indirect
2021-02-09	Convertible Promissory Note	$16	C		Disposed		Common Stock ()	Indirect

Footnotes

F1: Gilbert S. Omenn Revocable Trust.

F2: The convertible promissory note converted immediately prior to the consummation of the IPO into Common Stock.

F3: The convertible promissory note ("Convertible Note") had a maturity date of May 20, 2021 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $18.00 per Common Share.

F4: The convertible promissory note ("Convertible Note") had a maturity date of June 1, 2021 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $18.00 per Common Share.

F5: The convertible promissory note ("Convertible Note") had a maturity date of August 14, 2021 and the principal amount of the Convertible Note converted upon the closing of the IPO into Common Shares at a conversion price equal to $18.00 per Common Share.